International Journal of Radiation Oncology * Biology * Physics
Volume 81, Issue 3 , Pages 758-764 , 1 November 2011

Development of Late Toxicity and International Prostate Symptom Score Resolution After External-Beam Radiotherapy Combined With Pulsed Dose Rate Brachytherapy for Prostate Cancer

  • Bradley R. Pieters, M.D.

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • Corresponding Author InformationReprint requests to: Bradley R. Pieters., M.D., P.O. Box 22660, Z0-214, 1100 DD Amsterdam, The Netherlands. Tel: (+31) 020 5666824; Fax: (+31) 020 6091278
    • ,
  • Elisa Rezaie

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • ,
  • Elisabeth D. Geijsen, M.D.

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • ,
  • Kees Koedooder, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • ,
  • Johan N.B. van der Grient

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • ,
  • Leo E.C.M. Blank, M.D.

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands
    • ,
  • Theo M. de Reijke, M.D., Ph.D.

      Affiliations

    • Department of Urology, Academic Medical Center, University of Amsterdam, The Netherlands
    • ,
  • Caro C.E. Koning, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Academic Medical Center, University of Amsterdam, The Netherlands

Received 11 January 2010 ,Revised 7 April 2010 ,Accepted 24 May 2010.

References 

  1. Zelefsky MJ, Moughan J, Owen J, et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1053–1061
  2. Crook J, Fleshner N, Roberts C, et al. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol. 2008;179:141–146
  3. Phan TP, Syed AMN, Puthawala A, et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol. 2007;177:123–127
  4. Chin YS, Bullard J, Bryant L, et al. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol). 2006;18:474–479
  5. Vargas CE, Martinez AA, Boike TP, et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a Phase I to II study. Int J Radiat Oncol Biol Phys. 2006;66:416–423
  6. Kälkner KM, Wahlgren T, Ryberg M, et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up. Acta Oncol. 2007;46:909–917
  7. Keyes M, Miller S, Morovan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009;73:1023–1032
  8. Pieters BR, van der Grient JNB, Blank LECM, et al. Minimal displacement of novel self-anchoring catheters suitable for temporary prostate implants. Radiother Oncol. 2006;80:69–72
  9. Pieters BR, Geijsen ED, Koedooder K, et al. Treatment results of PDR brachytherapy combined with external beam radiotherapy in 106 patients with intermediate- to high-risk prostate cancer. Int J Radiat Oncol Biol Phys. In press.
  10. Martinez A, Galalae R, Gonzalez J, et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated wit a high total radiation dose. J Urol. 2003;170:2296–2301
  11. Martinez AA, Demanes DJ, Galalae R, et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys. 2005;62:1322–1331
  12. Hoskin PJ, Motohashi K, Bownes P, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol. 2007;84:114–120
  13. Merrick GS, Butler WM, Wallner KE, et al. Long-term rectal function after permanent prostate brachytherapy. Cancer J. 2007;13:95–104
  14. Yamada Y, Bhatia S, Zaider M, et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy. 2006;5:157–164
  15. Åström L, Pedersen D, Mercke C, et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol. 2005;74:157–161
  16. Martinez AA, Demanes J, Vargas C, et al. High-dose-rate prostate brachytherapy. An excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol. In press.
  17. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:119–124
  18. Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology. 2007;69:338–342
  19. Gutman S, Merrick GS, Butler WM, et al. Severity categories of International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. B J U Int. 2006;97:62–68
  20. Niehaus A, Merrick GS, Butler WM, et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:136–143
  21. van Gellekom MPR, Moerland MA, van Vulpen M, et al. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys. 2005;63:772–780
  22. Anderson JF, Swanson DA, Levy LB, et al. Urinary side effects and complications after permanent prostate brachytherapy: The MD Anderson Cancer Center experience. Urology. 2009;74:601–605
  23. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptom after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979–3986
  24. Litwin MS, Sadetsky N, Pasta DJ, et al. Bowel function and bother after treatment for early stage prostate cancer: A longitudinal quality of life analysis from CaPSURE. J Urol. 2004;172:515–519
  25. Soderdahl DW, Davis JW, Schellhammer PF, et al. Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer. J Endourol. 2005;19:318–326
  26. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: Health-related quality-of life changes after radical prostatectomy, external beam radiation, and brachytherapy. J Clin Oncol. 2005;23:2772–2780
  27. Kovács G, Pötter R, Loch T, et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol. 2005;74:137–148

 Conflict of interest: none.

PII: S0360-3016(10)00785-6

doi: 10.1016/j.ijrobp.2010.05.044

International Journal of Radiation Oncology * Biology * Physics
Volume 81, Issue 3 , Pages 758-764 , 1 November 2011

Article Tools

* Image Usage & Resolution